Skip to Content

Sinopharm Group Co Ltd SHTDF Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SHTDF

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SHTDF

Company Profile SHTDF

Business Description

Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 76% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Contact
No. 385, East Longhua Road, Sinopharm Group Building
Shanghai, 200023, China, People's Republic of
Industry Medical Distribution
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 113,234